Cargando…

SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis

BACKGROUND: SARS-CoV-2 seroepidemiological studies are used to guide public health decision making and to prepare for emerging infectious diseases. Disease occurrence estimates are limited in the Philippines, the country with the highest reported number of coronavirus disease-related deaths in the W...

Descripción completa

Detalles Bibliográficos
Autores principales: Malijan, Greco Mark B., Edwards, Tansy, Agrupis, Kristal An, Suzuki, Shuichi, Villanueva, Annavi Marie G., Sayo, Ana Ria, De Guzman, Ferdinand, Dimapilis, Alexis Q., Solante, Rontgene M., Telan, Elizabeth O., Umipig, Dorcas V., Ota, Kenji, Nishimura, Fumitaka, Yanagihara, Katsunori, Salazar, Mary Jane, Lopez, Edmundo B., Ariyoshi, Koya, Smith, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552163/
https://www.ncbi.nlm.nih.gov/pubmed/36221142
http://dx.doi.org/10.1186/s41182-022-00468-7
_version_ 1784806195517718528
author Malijan, Greco Mark B.
Edwards, Tansy
Agrupis, Kristal An
Suzuki, Shuichi
Villanueva, Annavi Marie G.
Sayo, Ana Ria
De Guzman, Ferdinand
Dimapilis, Alexis Q.
Solante, Rontgene M.
Telan, Elizabeth O.
Umipig, Dorcas V.
Ota, Kenji
Nishimura, Fumitaka
Yanagihara, Katsunori
Salazar, Mary Jane
Lopez, Edmundo B.
Ariyoshi, Koya
Smith, Chris
author_facet Malijan, Greco Mark B.
Edwards, Tansy
Agrupis, Kristal An
Suzuki, Shuichi
Villanueva, Annavi Marie G.
Sayo, Ana Ria
De Guzman, Ferdinand
Dimapilis, Alexis Q.
Solante, Rontgene M.
Telan, Elizabeth O.
Umipig, Dorcas V.
Ota, Kenji
Nishimura, Fumitaka
Yanagihara, Katsunori
Salazar, Mary Jane
Lopez, Edmundo B.
Ariyoshi, Koya
Smith, Chris
author_sort Malijan, Greco Mark B.
collection PubMed
description BACKGROUND: SARS-CoV-2 seroepidemiological studies are used to guide public health decision making and to prepare for emerging infectious diseases. Disease occurrence estimates are limited in the Philippines, the country with the highest reported number of coronavirus disease-related deaths in the Western Pacific region. We aimed to estimate SARS-CoV-2 seroprevalence and infection rate among outpatient clinic attendees in Metro Manila prior to the implementation of the national coronavirus disease vaccination program. METHODS: We conducted repeated cross-sectional surveys at the animal bite clinic in San Lazaro Hospital, Manila, the Philippines across four periods, 3 months apart, between May 2020 and March 2021. Multivariable logistic regression was used to assess associations between different characteristics and infection status including seropositivity. RESULTS: In total 615 participants were enrolled, ranging from 115 to 174 per period. Seroprevalence quadrupled between the first (11.3%) and second (46.8%) periods and plateaued thereafter (third—46.0%, fourth—44.6%). Among seropositive participants, total antibody concentration was comparable throughout the first to third periods but declined between the third and fourth periods. Infection prevalence was comparable across enrollment periods (range 2.9–9.5%). Post-secondary education [aOR 0.42 (95% CI 0.26, 0.67)] was protective, and frontline work [aOR 1.81 (95% CI 1.18, 2.80)] was associated with increased odds of seropositivity. Frontline work status [aOR 2.27 (95% CI 1.10, 4.75)] and large household size [aOR 2.45 (95% CI 1.18, 5.49)] were associated with increased odds of infection. CONCLUSIONS: The quadrupling of seroprevalence over 3 months between the first and second enrollment periods coincided with the high burden of infection in Metro Manila in early 2020. Our findings suggest a limit to the rise and potential decline of population-level SARS-CoV-2 infection-induced immunity without introduction of vaccines. These results may add to our understanding of how immunity develops against emerging infectious diseases including coronaviruses.
format Online
Article
Text
id pubmed-9552163
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95521632022-10-11 SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis Malijan, Greco Mark B. Edwards, Tansy Agrupis, Kristal An Suzuki, Shuichi Villanueva, Annavi Marie G. Sayo, Ana Ria De Guzman, Ferdinand Dimapilis, Alexis Q. Solante, Rontgene M. Telan, Elizabeth O. Umipig, Dorcas V. Ota, Kenji Nishimura, Fumitaka Yanagihara, Katsunori Salazar, Mary Jane Lopez, Edmundo B. Ariyoshi, Koya Smith, Chris Trop Med Health Research BACKGROUND: SARS-CoV-2 seroepidemiological studies are used to guide public health decision making and to prepare for emerging infectious diseases. Disease occurrence estimates are limited in the Philippines, the country with the highest reported number of coronavirus disease-related deaths in the Western Pacific region. We aimed to estimate SARS-CoV-2 seroprevalence and infection rate among outpatient clinic attendees in Metro Manila prior to the implementation of the national coronavirus disease vaccination program. METHODS: We conducted repeated cross-sectional surveys at the animal bite clinic in San Lazaro Hospital, Manila, the Philippines across four periods, 3 months apart, between May 2020 and March 2021. Multivariable logistic regression was used to assess associations between different characteristics and infection status including seropositivity. RESULTS: In total 615 participants were enrolled, ranging from 115 to 174 per period. Seroprevalence quadrupled between the first (11.3%) and second (46.8%) periods and plateaued thereafter (third—46.0%, fourth—44.6%). Among seropositive participants, total antibody concentration was comparable throughout the first to third periods but declined between the third and fourth periods. Infection prevalence was comparable across enrollment periods (range 2.9–9.5%). Post-secondary education [aOR 0.42 (95% CI 0.26, 0.67)] was protective, and frontline work [aOR 1.81 (95% CI 1.18, 2.80)] was associated with increased odds of seropositivity. Frontline work status [aOR 2.27 (95% CI 1.10, 4.75)] and large household size [aOR 2.45 (95% CI 1.18, 5.49)] were associated with increased odds of infection. CONCLUSIONS: The quadrupling of seroprevalence over 3 months between the first and second enrollment periods coincided with the high burden of infection in Metro Manila in early 2020. Our findings suggest a limit to the rise and potential decline of population-level SARS-CoV-2 infection-induced immunity without introduction of vaccines. These results may add to our understanding of how immunity develops against emerging infectious diseases including coronaviruses. BioMed Central 2022-10-11 /pmc/articles/PMC9552163/ /pubmed/36221142 http://dx.doi.org/10.1186/s41182-022-00468-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Malijan, Greco Mark B.
Edwards, Tansy
Agrupis, Kristal An
Suzuki, Shuichi
Villanueva, Annavi Marie G.
Sayo, Ana Ria
De Guzman, Ferdinand
Dimapilis, Alexis Q.
Solante, Rontgene M.
Telan, Elizabeth O.
Umipig, Dorcas V.
Ota, Kenji
Nishimura, Fumitaka
Yanagihara, Katsunori
Salazar, Mary Jane
Lopez, Edmundo B.
Ariyoshi, Koya
Smith, Chris
SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis
title SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis
title_full SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis
title_fullStr SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis
title_full_unstemmed SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis
title_short SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis
title_sort sars-cov-2 seroprevalence and infection rate in manila, philippines prior to national vaccination program implementation: a repeated cross-sectional analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552163/
https://www.ncbi.nlm.nih.gov/pubmed/36221142
http://dx.doi.org/10.1186/s41182-022-00468-7
work_keys_str_mv AT malijangrecomarkb sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT edwardstansy sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT agrupiskristalan sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT suzukishuichi sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT villanuevaannavimarieg sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT sayoanaria sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT deguzmanferdinand sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT dimapilisalexisq sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT solanterontgenem sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT telanelizabetho sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT umipigdorcasv sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT otakenji sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT nishimurafumitaka sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT yanagiharakatsunori sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT salazarmaryjane sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT lopezedmundob sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT ariyoshikoya sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis
AT smithchris sarscov2seroprevalenceandinfectionrateinmanilaphilippinespriortonationalvaccinationprogramimplementationarepeatedcrosssectionalanalysis